PMV Pharmaceuticals Inc. (PMVP) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    PMV Pharmaceuticals Inc.

    NASDAQ: PMVP · Real-Time Price · USD
    1.48
    0.08 (5.71%)
    At close: Sep 26, 2025, 3:59 PM
    1.43
    -3.38%
    After-hours: Sep 26, 2025, 05:40 PM EDT

    PMV Pharmaceuticals Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 1.14M 1.26M 650K 1.28M
    Gross Profit
    		 n/a -1.26M -650K -1.28M
    Operating Income
    		 -85.45M -80.13M -77.04M -58.29M
    Interest Income
    		 n/a 11.17M 3.63M 449K
    Pretax Income
    		 -74.81M -68.96M -73.33M -57.82M
    Net Income
    		 -58.71M -68.96M -73.32M -57.85M
    Selling & General & Admin
    		 26.92M 24.25M 25.05M 21.8M
    Research & Development
    		 58.53M 54.63M 51.99M 36.49M
    Other Expenses
    		 n/a n/a 87K 21K
    Operating Expenses
    		 85.45M 80.13M 77.04M 58.29M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 n/a 80.13M 77.04M 58.29M
    Income Tax Expense
    		 -16.1M 2K -9K 23K
    Shares Outstanding (Basic)
    		 51.58M 48.01M 45.59M 45.14M
    Shares Outstanding (Diluted)
    		 51.58M 48.01M 45.59M 45.14M
    EPS (Basic)
    		 -1.14 -1.44 -1.61 -1.28
    EPS (Diluted)
    		 -1.14 -1.44 -1.61 -1.28
    EBITDA
    		 -73.67M -78.88M -76.72M -57.99M
    EBIT
    		 -74.81M -80.13M -77.04M -58.29M
    Depreciation & Amortization
    		 1.14M 1.26M 650K 1.28M

    Add to Watchlist